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Myoclonic astatic epilepsy (MAE), or Doose syndrome, is a genet-
ically heterogenous rare childhood epilepsy syndrome character-
ized by the onset of myoclonic-atonic or atonic seizures between
the ages of 6 months and 6 years in a previously normally
developing child [Doose et al., 1970]. Typical febrile seizures
may precede afebrile seizures in two-thirds of cases. Other gener-
alized seizure types are frequently seen and electroencephalogram
(EEG) shows generalized spike wave or polyspike discharges on a
normal background. Prognosis is variable from complete seizure
remission, with normal or close to normal development, to a drug-
resistant epileptic encephalopathy. Approximately 10% of cases
can be attributed to mutations in SCN1A, SCN1B, GABRG2,
SLC2A1, CHD2, or SLC6A1, but the majority of cases remain
unexplained [Wallace et al., 1998, 2001; Escayg et al., 2001; Mullen
et al., 2011; Carvill et al., 2013; Carvill et al., 2015]. We report a
patient with MAE who, following exome sequencing, was subse-
quently diagnosed with Nicolaides–Baraitser syndrome (NCBRS)
(OMIM 601358). NCBRS was first described in 1993 and is an
intellectual disability andmultiple congenital anomalies syndrome
associatedwith seizures [Nicolaides and Baraitser, 1993]. Although
much of the phenotype is well delineated and includes sparse hair,
microcephaly, typical facial morphology, brachydactyly, promi-2016 The Authors. American Journal of Medical Genetics Partnent interphalangeal joints, and intellectual disability with marked
language impairment, the epilepsy features have not been well
described before.CLINICAL REPORT
A girl of Ghanaian ancestry was born at term with a birth weight of
3.4 kg (50thcentile) andaheadcircumferenceof32 cm(0.4thcentile).
Hermother reported normal early developmentalmilestones. She sat
unsupported at 8months,walked at12months, andwasbabbling just
before her first birthday. However, her mother had concerns that sheA published by Wiley Periodicals, Inc. 195
196 AMERICAN JOURNAL OF MEDICAL GENETICS PART Ahad reduced visual interest in people and did not smile readily.
Her first seizure was at 14 months and was a myoclonic atonic
seizure, which continued as her prominent seizure type while she
developed generalized tonic-clonic and absence seizures. Addition-
ally, the patient had feeding problems from 6 months following the
introduction of solids. She was hypersensitive to textures and dem-
onstrated food refusal and would hold food in her mouth or vomit
during meal times. Developmental assessment showed a delay in
language and social communication skills. No dysmorphic features
were identified at the time. At 17 months her weight was 10.7 kg
(50th–75th centile), height 82.5 cm (75th–91st centile), head circum-
ference 48 cm (98th–99.6th centile). At 2 years 9 months, her weight
was 13.9 kg (25th–50th centile), height 94.7 cm (50th–75th centile),
and she had developed relative microcephaly with her head circum-
ference at 49 cm (9th–25th centile). Her EEG demonstrated frequent
generalized bursts of polyspike and wave activity during wakefulness
and sleepagainst anormal background.Anelectrographic correlate of
negative axial myoclonus was captured (see Supplementary informa-
tion Figs. S1 and S2). An MRI brain scan was normal. Array CGH
analysiswith44,000probesacross thegenomewasnormal.Basedon
these electroclinical features, her epilepsy type was thought compati-
blewith adiagnosis ofMAE. Shewas treatedwith sodiumvalproate to
which she responded, attaining complete seizure remission at 3 years
with normalization of her EEG. Antiepileptic medication was dis-
continued at 4 years.
The patient was reviewed at 5 years. She had developed a
restricted pattern of feeding with aversion to lumpy foods. The
3Di autism interview revealed abnormalities in communication
and non-verbal communication, with borderline scores in social
reciprocity and restricted/repetitive behavior and interests, and she
was diagnosed with autism spectrum disorder. On neurodevelop-
mental assessment with the Wechsler Preschool and Primary Scale
of Intelligence III, she demonstrated severe learning difficulties and
scored 51 for Verbal IQ (0.1th centile), 57 for Performance IQ
(0.2th centile), and 47 for Full Scale IQ (<0.1 centile). Repeat
awake and sleep EEG and repeat MRI brain scans were normal.
Exome sequencing of the patient at the age of 5 years and her
parents confirmed paternity and identified a novel de novo
SMARCA2 missense mutation c.3721C>G; p.Gln1241Glu
(ENST00000349721NM_0030703), confirmed by Sanger sequenc-
ing in the patient. (See Fig. 1a and b for IGV plot and Sanger
sequencing chromatogram, respectively). This novel variant is
highly conserved and not reported in 1000G, ExAC, or EVS. In
the ExAC database, nonsynonymousmissense, stopgain, and splice
variants in exon 26 are very rare with MAF< 0.0001 and one splice
variant with MAF 0.001–0.0001. Annotation from insilico predic-
tion tools was SIFT 0.184 (tolerated), PolyPhen2 0.900 (possibly
damaging), mutation taster 0.999 (disease causing), and CADD
22.5 (top 1% most deleterious).
Following the exome sequencing findings, we reviewed her
clinical examination at 5 years 5 months and observed skin
wrinkling, frontal balding, a broad and long philtrum, broad nasal
base, upturned nasal tip, thick alae nasi, anterior projection of the
upper lip over the premaxilla, and thin upper vermillion and thick
lower vermillion border. She had slightly thick distal phalanges in
the hands. (See Fig. 2a–d for clinical photographs). She had eczema
particularly involving the elbows and knees. Her clinical phenotypeof specific craniofacial features, reduced speech, intellectual dis-
ability, autism, and seizures along with a de novo SMARCA2
mutation was consistent with the Nicolaides–Baraitser syndrome
spectrum (NCBRS) [Sousa and Hennekam, 2014].
The institutional review boards and ethical committees of King’s
Health Partners approved the study. The participants gave written
informed consent in accordance with the Declaration of Helsinki.DISCUSSION
We report a patient with MAE and features of NCBRS. Although
seizures are reported in two-thirds of patients withNCBRS, neither
seizure semiology nor specific epilepsy syndromes have been well
described. The patient described in this study was diagnosed with
MAE syndrome and the diagnosis of NCBRS in this patient was
only made following identification of the SMARCA2mutation and
clinical re-examination. This was because the NCBRS phenotype is
progressive and in younger ages the features are subtle and difficult
to recognize. Moreover, there is no reported association between
MAE and NCBRS. A specific role for SMARCA2 mutations has
been implicated in NCBRS with at least 80% of patients carrying a
mutation in SMARCA2 (OMIM 601358) [Van Houdt et al., 2012],
but to our knowledge all causative mutations have been located in
exons 15–25, and never before in exon 26. SMARCA2 is a chroma-
tin remodeling gene, and mutations in another gene involved in
this pathway CHD2 are known to cause MAE, suggesting this
pathway as a potential therapeutic target [Carvill et al., 2013].
There are no reported specific seizure phenotypes or EEG abnor-
malities for NCBRS, although epilepsy occurs in two-thirds of
patients. In a series of 61 individuals with NCBRS, the median
age at the first seizure was 18months [Sousa andHennekam, 2014].
Additionally, as in ourpatient, a co-occurrence of decreasingmental
abilities with the onset of seizures (epileptic encephalopathy) in
NCBRS has been observed [Sousa and Hennekam, 2014]. Epileptic
encephalopathy is also frequent inMAE,and it ispossible that theco-
existence of NCBRS /MAE is more common than expected.
SMARCA2 is located on chromosome 9p24.3 and its longest
transcript has 34 exons. Thus far, 62 missense mutations and three
in-frame deletions clustering in the ATPase domains of exons
15–25 of SMARCA2 have been reported in patients with NCBRS
[Sousa and Hennekam, 2014; Bramswig et al., 2015; Ejaz et al.,
2016] (see Fig. 3 for schematic diagram of SMARCA2 protein and
location of mutations). These mutations are thought to have a
dominant negative effect by abolishing the ATP hydrolyzing engine
potential of the protein, removing the ability of the protein to
reposition histones on DNA. Recently, one other patient with
NCBRS but no seizures has been reported to carry a mutation
c.3655G>C, pAla1219Pro, located outside but close to the ATPase
domain, [Bramswig et al., 2015]. To our knowledge, the patient
reported here carries the first mutation located in exon 26, also in
close proximity of the ATPase domain. We hypothesize that both
mutations similarly affect ATP hydrolysis and chromatin remod-
eling ability. Sousa and Hennekam [2014] reported a case with a
mutation in the Bromo domain, in exon 30 (p.Gly1420Arg). Their
case did not have the typical facial features seen in NCBRS but had
overlap features of severe intellectual disability, absent speech and
seizures. The absence of mutations reported outside exons 15–25
FIG. 1. a: IGV plot demonstrating the de novo SMARCA2 mutation; patient (top), mother (middle), and father (bottom). b: Sanger sequencing
chromatogram of the patient’s SMARCA2 mutation. [Color figure can be viewed at wileyonlinelibrary.com].
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ing other areas of the gene based on previous association [Sousa
and Hennekam, 2014]. Based on our findings, we would suggest
incorporating exon 26 in clinical laboratory testing.
Genetic aberrations involving exon 26 in addition to ATPase
disruption have also been described. NCBRS has been reported
with a 32 kb de novo in-frame SMARCA2 deletion affecting exons
20–26 [Wolff et al., 2012] and a 55 kb interstitial deletion involving
exons 20–27 was reported in a patient with the phenotypically
similar Coffin–Siris syndrome [Tsurusaki et al., 2014]. These
patients had epilepsy, but the associated seizure semiology and
epilepsy syndromes merit further description.SMARCA2 is one of the six genes that encodes the catalytic
subunit components of the SWItch/sucrose nonfermentable
like chromatin-remodeling complex (SWI/SNF complex). The
SWI/SNF complex is evolutionarily highly conserved from yeast
to humans and works as a chromatin remodeler, altering chroma-
tin structure through ATP hydrolysis. SWI/SNF proteins regulate
gene expression by re-positioning nucleosomes and altering DNA
transcription. A close connection between the SWI/SNF complex
and neurological development has been implicated through the
identification of numerous mutations in genes encoding the sub-
units in a range of neurodevelopmental disorders such as Coffin–
Siris syndrome, sporadic intellectual disability, autism spectrum-
FIG. 2. a and b: Clinical photographs demonstrating features of skin wrinkling, frontal balding, broad nasal base, upturned nasal tip, thick alae
nasi, broad and long philtrum, thin upper vermillion, and thick lower vermillion, anterior projection of the upper lip over the premaxilla. c: Clinical
photographs of hands with slightly thick distal phalanges. d: Clinical photograph of feet. [Color figure can be viewed at wileyonlinelibrary.com].
FIG. 3. Schematic diagram of SMARCA2 protein and its domains and location of missense mutations associated with NCBRS. QLQ, glutamine-
leucine-glutamine domain; Proline, proline-rich domain; HSA, small helicase/SANT associated domain; BRK, brahma and kismet domain; SNF2_N
and Helicase_C; Bromo, acetyl-lysine binding bromodomain. Patient’s mutation in black. Mutations reported first by [Van Houdt et al., 2012] in
green, [Wolff et al., 2012] in orange, [Sousa and Hennekam, 2014] in blue, [Bramswig et al., 2015] in purple, and [Ejaz et al., 2016] in pink.
Recurrent mutations. Patient without classical NCBRS but with overlap features of intellectual disability, absent speech and seizures.
[Color figure can be viewed at wileyonlinelibrary.com].
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Crabtree, 2014].
We conclude that (i) NBCRS spectrum features can be caused by
mutations outside the ATPase region of SMARCA2; and that (ii)
the epilepsy phenotype in NBCRS can be consistent with MAE
syndrome. This study underlines the fact that, in rare genetically
heterogeneous conditions like MAE, where the patient is primarily
under the care of a non-clinical specialist geneticist, exome
sequencing can help aid in making clinical syndromic diagnosis.INTERNET SOURCES
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